BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Chronic Myeloid Leukemia
Leukemia, Lymphoblastic, Acute, Philadelphia-positive

Interventions: Drug: Dasatinib

First Posted Date: 2005-01-13

Last Posted Date: 2011-04-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 96

Registration Number: NCT00101595

Locations: 🇬🇧
Local Institution, London, Greater London, United Kingdom

Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

Phase 2

Completed

Conditions: Transitional Cell Carcinoma
Bladder Neoplasms
Kidney Neoplasms
Ureter Neoplasms
Bladder Cancer
Neoplasm, Bladder

Interventions: Drug: vinflunine

First Posted Date: 2005-01-13

Last Posted Date: 2010-03-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 150

Registration Number: NCT00101608

Locations: 🇹🇭
Local Institution, Bangkok, Thailand
🇨🇦
Local Insitution, Toronto, Ontario, Canada

Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer

Phase 2

Terminated

Conditions: Non-small Cell Lung Cancer

First Posted Date: 2004-12-22

Last Posted Date: 2010-03-02

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT00099879

Locations: 🇳🇱
Local Insitution, Groningen, Netherlands
🇬🇧
Local Institution, Manchester, United Kingdom

Phase I (PH I) Mad Refractory Solid Tumor Study

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Dasatinib

First Posted Date: 2004-12-20

Last Posted Date: 2011-04-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 60

Registration Number: NCT00099606

Locations: 🇬🇧
Local Institution, Glasgow, Strathclyde, United Kingdom

BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery

Phase 2

Completed

Conditions: Venous Thrombosis
Pulmonary Embolism

Interventions: Drug: Apixaban
Drug: Enoxaparin
Drug: Warfarin
Drug: Enoxaparin Placebo
Drug: Apixaban Placebo

First Posted Date: 2004-11-23

Last Posted Date: 2010-03-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1238

Registration Number: NCT00097357

Locations: 🇵🇷
Local Institution, Ponce, Puerto Rico

Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program

Conditions: Hepatitis B
Chronic Disease

First Posted Date: 2004-11-16

Last Posted Date: 2016-09-21

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT00096811

Locations: 🇮🇱
Local Institution, Zefat, Israel

Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B Infection

Phase 3

Completed

Conditions: Hepatitis B
Chronic Disease

Interventions: Drug: entecavir
Drug: adefovir

First Posted Date: 2004-11-16

Last Posted Date: 2010-08-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 69

Registration Number: NCT00096785

Locations: 🇹🇭
Local Institution, Bankok, Thailand
🇺🇸
Local Insitution, New York, New York, United States

Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected Subjects

Completed

Conditions: HIV Infection

Interventions: Drug: LPV/RTV + 2NRTIs

First Posted Date: 2004-11-16

Last Posted Date: 2011-04-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 200

Registration Number: NCT00096746

Locations: 🇿🇦
Local Institution, Rugby, Western Cape, South Africa
🇺🇸
Local Instution, Lexington, Kentucky, United States

A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Antidepressant + Placebo
Drug: Antidepressant + Aripiprazole

First Posted Date: 2004-11-09

Last Posted Date: 2013-11-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1200

Registration Number: NCT00095758

Locations: 🇺🇸
Local Institution, Middleton, Wisconsin, United States

A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Antidepressant + Placebo
Drug: Antidepressant + Aripiprazole

First Posted Date: 2004-11-09

Last Posted Date: 2013-11-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1200

Registration Number: NCT00095823

Locations: 🇺🇸
Local Institution, Middleton, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy